BACKGROUND: The first therapeutic choice for the treatment of cutaneous sporotrichosis is oral itraconazole; however, the increase in cases of zoonotic transmission outbreak necessitates a search for effective and safe treatment alternatives. OBJECTIVE: To evaluate a new potassium iodide (KI) posology as an alternative for the treatment of limited cutaneous forms of sporotrichosis. METHODS: One hundred and two patients with sporotrichosis diagnosed by isolation of Sporothrix sp. were included and were divided into 2 groups that received different doses of KI: group A received the conventional dose, and group B received the reduced dose. The cure criteria were based on clinical and serological data. RESULTS: Seventy-nine patients (77.4%) reached clinical cure: 70.6% and 84.3% of groups A and B respectively. Sixteen patients (15.6%) were lost during follow-up, and seven changed drug therapy: five in group A and two in group B. The incidence of adverse events was similar for both groups (64.7%): predominantly metallic taste (44%), followed by mild gastrointestinal intolerance and acneiform eruption (10.7% each). No serious adverse events occurred, and there were no recurrences. Analysis of the results showed no statistically significant difference between groups (P = 0.9255). The improvement in serologic titres was significant in both treatment groups. CONCLUSION: Through statistical analysis, the usual posology was not shown to be superior to the one proposed in this study. Serology for sporotrichosis may be used as a valuable tool in the clinical monitoring of these patients.
BACKGROUND: The first therapeutic choice for the treatment of cutaneous sporotrichosis is oral itraconazole; however, the increase in cases of zoonotic transmission outbreak necessitates a search for effective and safe treatment alternatives. OBJECTIVE: To evaluate a new potassium iodide (KI) posology as an alternative for the treatment of limited cutaneous forms of sporotrichosis. METHODS: One hundred and two patients with sporotrichosis diagnosed by isolation of Sporothrix sp. were included and were divided into 2 groups that received different doses of KI: group A received the conventional dose, and group B received the reduced dose. The cure criteria were based on clinical and serological data. RESULTS: Seventy-nine patients (77.4%) reached clinical cure: 70.6% and 84.3% of groups A and B respectively. Sixteen patients (15.6%) were lost during follow-up, and seven changed drug therapy: five in group A and two in group B. The incidence of adverse events was similar for both groups (64.7%): predominantly metallic taste (44%), followed by mild gastrointestinal intolerance and acneiform eruption (10.7% each). No serious adverse events occurred, and there were no recurrences. Analysis of the results showed no statistically significant difference between groups (P = 0.9255). The improvement in serologic titres was significant in both treatment groups. CONCLUSION: Through statistical analysis, the usual posology was not shown to be superior to the one proposed in this study. Serology for sporotrichosis may be used as a valuable tool in the clinical monitoring of these patients.
Authors: Rosane Orofino-Costa; Dayvison Francis Saraiva Freitas; Andréa Reis Bernardes-Engemann; Anderson Messias Rodrigues; Carolina Talhari; Claudia Elise Ferraz; John Verrinder Veasey; Leonardo Quintella; Maria Silvia Laborne Alves de Sousa; Rodrigo Vettorato; Rodrigo de Almeida-Paes; Priscila Marques de Macedo Journal: An Bras Dermatol Date: 2022-09-22 Impact factor: 2.113
Authors: Rodrigo do Carmo Silva; Dayvison Francis Saraiva Freitas; João Pedro Cabrera Pereira; Antonio Carlos Francesconi do Valle; Maria Clara Gutierrez-Galhardo; Fernando Almeida-Silva; Felipe Mauricio Soeiro Sampaio Journal: JAAD Case Rep Date: 2022-06-22
Authors: Olga Fischman Gompertz; Anderson M Rodrigues; Geisa F Fernandes; Henri D L Bentubo; Zoilo Pires de Camargo; Valéria Petri Journal: Am J Trop Med Hyg Date: 2016-04-25 Impact factor: 2.345
Authors: Vivian S Baptista; Gabriele Barros Mothé; Giulia M P Santos; Carla Stefany I Melivilu; Thayana O Santos; Emylli D Virginio; Pãmella A de Macêdo-Sales; Márcia Ribeiro Pinto; Ricardo Luiz D Machado; Elisabeth M S Rocha; Leila Maria Lopes-Bezerra; Andréa Regina S Baptista Journal: Braz J Microbiol Date: 2020-08-18 Impact factor: 2.476
Authors: Rosane Orofino-Costa; Priscila Marques de Macedo; Anderson Messias Rodrigues; Andréa Reis Bernardes-Engemann Journal: An Bras Dermatol Date: 2017 Sep-Oct Impact factor: 1.896
Authors: Rodrigo Almeida-Paes; Fábio Brito-Santos; Maria Helena Galdino Figueiredo-Carvalho; Ana Caroline Sá Machado; Manoel Marques Evangelista Oliveira; Sandro Antonio Pereira; Maria Clara Gutierrez-Galhardo; Rosely Maria Zancopé-Oliveira Journal: Mem Inst Oswaldo Cruz Date: 2017-05 Impact factor: 2.743
Authors: Regina Casz Schechtman; Eduardo Mastrangelo Marinho Falcão; Marciela Carard; Maria Salomé Cajas García; Diana Stohmann Mercado; Roderick James Hay Journal: An Bras Dermatol Date: 2021-12-08 Impact factor: 1.896
Authors: George R Thompson; Thuy Le; Ariya Chindamporn; Carol A Kauffman; Ana Alastruey-Izquierdo; Neil M Ampel; David R Andes; Darius Armstrong-James; Olusola Ayanlowo; John W Baddley; Bridget M Barker; Leila Lopes Bezerra; Maria J Buitrago; Leili Chamani-Tabriz; Jasper F W Chan; Methee Chayakulkeeree; Oliver A Cornely; Cao Cunwei; Jean-Pierre Gangneux; Nelesh P Govender; Ferry Hagen; Mohammad T Hedayati; Tobias M Hohl; Grégory Jouvion; Chris Kenyon; Christopher C Kibbler; Nikolai Klimko; David C M Kong; Robert Krause; Low Lee Lee; Graeme Meintjes; Marisa H Miceli; Peter-Michael Rath; Andrej Spec; Flavio Queiroz-Telles; Ebrahim Variava; Paul E Verweij; Ilan S Schwartz; Alessandro C Pasqualotto Journal: Lancet Infect Dis Date: 2021-08-06 Impact factor: 71.421
Authors: Marcelo Rosandiski Lyra; Vanessa Sokoloski; Priscila Marques de Macedo; Anna Carolina Procópio de Azevedo Journal: An Bras Dermatol Date: 2021-01-31 Impact factor: 1.896